Lyophilised peptide
Retaovotride
40 mg
40 mg lyophilised vial supplied with 0.9% saline ampoule.
- Presentation
- 40 mg lyophilised powder vial + 0.9% saline ampoule
- Pharmaceutical form
- Powder for solution for injection
- Route of administration
- Subcutaneous
- Storage
- Store vial at 2 to 8 °C. Reconstitute immediately before use.
For clinical, packaging or regulatory enquiries, contact our medical information team.
Make an enquiryProduct information
Overview
The 40 mg Retaovotride presentation follows the same vial and ampoule format as the 20 mg strength, with a higher powder fill for reconstitution to a stronger working concentration.
Presentation details
- Higher fill weight per vial
- Identical reconstitution workflow to 20 mg
- Wave graphic carton for range consistency
Specification
- Active ingredient
- Retaovotride
- Presentation
- Lyophilised vial
- Diluent
- 0.9% sodium chloride, 1 ampoule
- Closure
- Blue flip off aluminium seal
- Pack
- 1 vial + 1 ampoule
- Marking
- For subcutaneous use only
